Nogapendekin alfa inbakicept-pmln

Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP) Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on. NEW YORK, May 29, 2026 /PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three separate drug candidates already dosing patients in human trials, a technology platform exclusively licensed from the University of Minnesota, and a scientific approach that the largest names in cancer immunotherapy are spending billions to pursue. See the full GT Biopharma investor breakdown at USA News Group → That gap — between what the company is doing in the clinic and what the market is paying for it — is the entire story. Whether it closes, and in which direction, is the question every investor reading this should be weighing right now. The idea: don't build a new weapon, sharpen the one you already have Most cancer therapies try to bolt something new onto the body — a manufactured cell, a synthetic antibody, a toxic payload. GT Biopharma's approach is different, and once you understand it, it's hard to forget. The human immune system already contains a class of cells whose entire job is to find and destroy abnormal cells: natural killer cells, or NK cells. They are the immune system's first responders, patrolling the body and killing threats without needing to be "trained" first. The problem in cancer is that tumors learn to hide from them. GT Biopharma's platform, called TriKE® — short for Tri-specific Killer Engager — is designed to drag those NK cells directly onto the tumor and switch them on. A TriKE molecule is engineered with three parts joined together. One arm grabs the NK cell by a receptor called CD16. A second arm grabs the cancer cell by a marker on its surface. And in the middle sits a molecule called IL-15, which acts like a shot of adrenaline, keeping the NK cell alive and multiplying once it's locked onto its target. The result, in concept, is elegant: you take the body's existing assassins, handcuff them to the tumor, and tell them to get to work. The platform was developed at the University of Minnesota, and GT Biopharma holds an exclusive worldwide license to develop and commercialize therapies based on it. This is not a science project the company dreamed up in isolation — it's institutional research that GTBP has the rights to turn into medicine. Why now: three shots on goal, all live What changed in 2026 is that GT Biopharma stopped being a one-drug story. As of this spring, the company has advanced three TriKE candidates into the clinic — a milestone its leadership rightly calls a turning point. Track every clinical milestone on the GTBP catalyst timeline → The lead program is GTB-3650, aimed at relapsed or refractory CD33-positive blood cancers — specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), two of the most treatment-resistant cancers in oncology. It is the first TriKE built on camelid nanobody technology — antibody fragments derived from the same family as llamas and alpacas, prized for being small, stable, and able to penetrate tissue. The Phase 1 dose-escalation trial began enrolling in early 2025 and has moved methodically upward through its dose cohorts. As of the company's Q1 2026 report in May, Cohort 4 enrollment was complete with eight patients treated across the first four cohorts — and, critically, the earlier safety reviews advanced without the dose-limiting toxicities that derail so many early trials. The study can escalate through up to seven cohorts, and management has guided to a meaningful data update in the second half of 2026. The newest program is where the ambition becomes obvious. In May 2026, GT Biopharma dosed the first patient in the Phase 1 trial of GTB-5550, a TriKE targeting a protein called B7-H3. Here is why that matters: B7-H3 is expressed on a huge range of solid tumors, and in metastatic castration-resistant prostate cancer it appears in over 90% of tumors. The trial begins with a prostate-cancer-focused dose escalation, then expands into a "basket" across as many as seven solid tumor types — prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder. In the company's own framing, the solid-tumor patient population GTB-5550 targets is "orders of magnitude larger" than the blood-cancer population of its lead drug. And GTB-5550 uses subcutaneous dosing — a simple injection rather than an infusion — which the company describes as more patient-friendly, a quiet but real commercial advantage if the drug works. Three programs. Two cancers as different as liquid and solid tumors. One underlying platform. That is the shape of a company trying to prove a technology, not just a single molecule. The market it's chasing is enormous The backdrop here is not subtle. The global oncology market is projected to nearly double from roughly $139 billion in 2025 to about $268 billion by 2034. Solid tumors alone represent a market estimated in the hundreds of billions of dollars, and B7-H3 — GTB-5550's target — shows up across many of the most common and lethal of them. NK-cell-directed immunotherapy has become one of the most closely watched frontiers in the entire sector, precisely because it offers the prospect of harnessing the immune system with potentially fewer of the brutal side effects of conventional treatment. Why NK-cell therapy is biotech's hottest frontier — read the deep dive → When a tiny company is pointed at a market that large, the math of asymmetry takes over. It does not require GT Biopharma to win the whole field. It requires only that one of its three shots connects — and that the market eventually notices a company priced near $13 million is playing in an arena measured in the hundreds of billions. How GT Biopharma stacks up against its NK-cell peers The most useful way to understand GTBP's positioning is to look at the company it keeps. NK-cell and immune-engager therapy is a crowded, well-funded field — and the contrast in scale is the entire investment argument. ImmunityBio (NASDAQ: IBRX) is the proof of concept that NK-cell immunotherapy can reach the market. Its NK-activating therapy ANKTIVA is FDA-approved for bladder cancer, the company reported roughly $44 million in product revenue in Q1 2026 and held some $381 million in cash, and it is now scaling NK-cell manufacturing to billions of cells per batch. ImmunityBio is what NK-cell success looks like at commercial scale — and a reminder of the valuation gap a clinical-stage peer could theoretically narrow if its data delivers. Fate Therapeutics (NASDAQ: FATE) is the deep-pocketed platform play, engineering off-the-shelf NK and CAR-T cell therapies from induced pluripotent stem cells, with roughly $175 million in cash and a runway management has guided into 2028. Fate illustrates how richly the market will fund an NK/cell-therapy platform it believes in — a striking counterpoint to GTBP's microcap valuation. Nkarta (NASDAQ: NKTX) is the engineered-NK-cell specialist, advancing its platform into autoimmune disease and backed by a market capitalization and cash position orders of magnitude above GT Biopharma's. Nkarta shows that NK-cell companies can command substantial valuations well before commercialization, on the strength of platform potential alone. Artiva Biotherapeutics (NASDAQ: ARTV) rounds out the set as the allogeneic, off-the-shelf NK-cell developer whose lead candidate AlloNK is heading toward a Phase 3 registrational trial in refractory rheumatoid arthritis in 2026. Artiva demonstrates how far and how fast an NK-cell program can advance through the clinic — the kind of trajectory GTBP investors are betting its TriKE platform can follow. Set GT Biopharma beside those four names and the picture sharpens. They are pursuing variations of the same fundamental thesis — unleash NK cells against disease — and the market has assigned them valuations ranging from the hundreds of millions into the billions. GT Biopharma, with three candidates already in the clinic, sits near $13 million. Either the market has correctly priced a struggling microcap, or it has badly overlooked a platform company in the same arena as far larger peers. That is the bet, stated plainly. The risks, stated honestly No serious investor case is complete without the other side of the ledger, and GT Biopharma's is real. This is a clinical-stage company with no approved products and no product revenue. Its cash balance was approximately $9 million at the end of Q1 2026, which management expects to fund operations only through the fourth quarter of 2026 — meaning additional financing, likely dilutive to existing shareholders, is a near-certainty rather than a possibility. The stock trades well under a dollar and far below its 52-week high, and a Roth Capital analyst, while maintaining a Buy rating, cut the price target to $3 from $8 earlier this year. Phase 1 trials are designed to test safety, not to prove a drug works; the encouraging absence of dose-limiting toxicities and the early signs of NK-cell activation are genuinely positive, but they are not efficacy. Most drugs that enter Phase 1 never reach the market. And the very peers that make GTBP look cheap are also formidable competitors with vastly greater resources. In short: this is a high-risk, binary-outcome situation. It is exactly the kind of company that can multiply many times over on a single strong data readout — and exactly the kind that can be forced into painful dilution or worse if the data disappoints or the financing window closes. Both outcomes are live. The bottom line GT Biopharma is a study in asymmetry. On one side: a roughly $13 million valuation, a sub-dollar stock, a thin cash runway, and all the risk that comes with clinical-stage biotech. On the other: three drugs dosing patients, a platform licensed from a top-tier research university, a mechanism the biggest players in immuno-oncology are validating with their own R&D budgets, and a pair of catalysts — GTB-3650 data and GTB-5550 progress — both expected in the second half of 2026. That is the setup. A company priced for failure, sitting on a platform built for something much larger, with hard data events on the calendar in a matter of months. For investors who understand that the biggest biotech returns come from the names the market has written off just before it's forced to reconsider, GT Biopharma is a story worth watching very closely between now and year-end. Get the full GTBP investor profile, pipeline, and catalyst calendar at USA News Group → CONTACT: USA News Group [email protected] 604-265-2873 Sources: GT Biopharma, Inc., "GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors," GlobeNewswire, May 14, 2026. GT Biopharma, Inc., "GT Biopharma Reports First Quarter 2026 Financial Results," May 15, 2026 (Cohort 4 complete, 8 patients across first four cohorts; ~$9M cash to Q4 2026; 2H 2026 updates). GT Biopharma, Inc., IND submission / pipeline overview — TriKE mechanism (camelid anti-CD16 / scFv anti-CD33 / IL-15), GTB-3650 dose-escalation design (up to 7 cohorts, ~14 patients), GTB-5550 design and B7-H3 >90% in mCRPC; gtbiopharma.com product pipeline. Roth Capital analyst note (Jonathan Aschoff), price target revised to $3 (Buy), 2026. Global Market Insights Inc. oncology market size ($139.4B 2025 → $268.3B 2034); Data Bridge Market Research solid-tumor market context. ImmunityBio (NASDAQ: IBRX) Q1 2026 results and NK-cell manufacturing release, 2026. Fate Therapeutics (NASDAQ: FATE) Q1 2026 results (runway into 2028), May 13, 2026. Nkarta (NASDAQ: NKTX) corporate/clinical disclosure, 2026. Artiva Biotherapeutics (NASDAQ: ARTV) corporate disclosure / AlloNK Phase 3 plan, 2026. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by USA News Group on behalf of MIQ. MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Direct Marketing Group ("CDMG"). There may be 3rd parties who may have shares of GT Biopharma, Inc. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. The owner/operator of MIQ currently owns shares of GT Biopharma, Inc. that were purchased in the open market and reserves the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of GT Biopharma, Inc. by CDMG; this is a digital media distribution. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo: SOURCE USA News Group 21% more press release views with Request a Demo

点击蓝字 关注我们 据“AJMC”相关报道，现成异基因CAR-NK细胞疗法联合利妥昔单抗，可在不使用化疗的前提下，帮助华氏淋巴瘤患者实现长期病情缓解，一例CR长达15个月，且后续未再进行其他治疗。该疗法是首款无需化疗、无需淋巴细胞清除的CAR-NK方案。所有治疗均可在门诊完成。疗法同时靶向CD19与CD20靶点，抗肿瘤效果显著；其起效快、疗效持久的特点，也契合当下肿瘤限时治疗的发展方向，为癌症患者带来新的希望与选择！ ▲截图源自“AJMC” 门诊式CAR-NK免疫疗法亮剑难治性淋巴瘤，一例CR长达15个月 本文开篇提到的这项QUILT-106（NCT06334991）临床研究，采用可表达高亲和力CD16受体的基因工程CD19特异性CAR-NK细胞，依托双重作用机制联合利妥昔单抗，显著提升抗肿瘤活性。研究针对治疗手段匮乏、经标准靶向及抗体治疗后复发耐药的罕见B细胞恶性肿瘤——华氏非霍奇金淋巴瘤，精准解决临床治疗难题。 该疗法支持门诊全程施治，无需化疗及淋巴细胞清除预处理，有效规避传统治疗毒副作用。试验统一给药方案为21天一个疗程，共4个疗程，累计输注8剂CAR-NK细胞与6剂利妥昔单抗，治疗全程无需额外辅助干预，并在完成2个疗程后开展疗效评估。 长期随访数据显示：两例难治性患者均获得持久完全缓解（CR）。其中多发淋巴瘤骨病灶患者，完全缓解状态已维持7个月，疗效可通过PET扫描直观验证（详见下图）；骨髓肿瘤浸润率达95%的重度受累患者，仅4剂联合治疗即实现骨髓形态学完全缓解，完成全部疗程且无后续治疗干预的情况下，缓解时长已达15个月并持续保持。 ▲图源“Nat Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 本研究首次证实，无化疗、无预处理的门诊式异基因CD19 CAR-NK联合利妥昔单抗方案，为血液肿瘤领域带来新的曙光！ CAR-NK联合疗法重创胶质母细胞瘤，82.6%患者获得持续生存获益 一项Ⅱ期QUILT-3.078临床试验，评估了ANKTIVA®联合PD-L1 t-haNK、贝伐珠单抗及肿瘤电场疗法，治疗复发性胶质母细胞瘤的临床效果。ⅡB期试验采用1:1随机分组设计，对照组采用ANKTIVA+贝伐珠单抗+肿瘤电场疗法，试验组在此基础上新增PD-L1 t-haNK联合治疗。本次研究整体纳入23例经常规手术、放疗、替莫唑胺化疗后疾病进展的复发/进展性患者。 结果显示：23例患者中19例存活，生存获益比例达82.6%。其中14例可评估患者构成疗效分析队列，累计接受139剂联合免疫治疗，目前患者中位总生存期尚未达到（详见下图）。 ▲图源“immunitybio”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 影像学结果直观证实，代表性患者接受CAR-NK联合治疗后，肿瘤病灶显著缩小。 ▲图源“immunitybio”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 CCCR-NK92疗法，助肺癌病灶显著缩小 全球知名期刊《Cell Transplantation（细胞移植）》刊发过一个振奋的临床案例，证实改良型CAR-NK疗法——CCCR-NK92，对晚期非小细胞肺癌具备明确治疗活性。 本次案例为一名69岁晚期非小细胞肺癌女性患者，基因检测提示T790突变、Exon-19缺失突变，合并颅内转移，既往经吉非替尼、奥西替尼靶向治疗及头部放疗后病情仍进展。患者因担忧化疗副作用拒绝常规化疗，最终符合入组条件，参与CCCR-NK92疗法治疗晚期非小细胞肺癌的Ⅱ期临床试验（NCT03656705）。 结果显示：患者完成3个周期CAR-NK治疗后，影像学复查显示病灶明显缩小：气管前-后腔静脉间质区淋巴结由11.3mm缩减至8.55mm，左肺包裹性胸腔积液由46.22mm缩减至33.59mm（详见下图），充分验证了该疗法对晚期肺癌的干预价值。 ▲图源“Sage Journals”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 CD19 CAR-NK疗法强效对抗白血病，治疗30天病灶完全消退 《新英格兰医学杂志》刊发MD安德森癌症中心重磅临床研究（NCT03056339），证实靶向CD19的CAR-NK细胞疗法，对CD19阳性恶性肿瘤具备优异的治疗效果，临床数据极具突破性。 研究中一例发生Richter转化的慢性淋巴细胞白血病患者，经CAR-NK细胞输注治疗后成效显著。 结果显示：输注30天后PET-CT复查显示，高级别淋巴瘤病灶完全消退，氟脱氧葡萄糖摄取转为阴性。患者虽初期存在血细胞减少、骨髓残留病灶等问题，但最终成功实现完全缓解（CR），充分彰显了CD19 CAR-NK疗法强效、持久的抗肿瘤能力。 ▼5号患者在CAR-NK细胞治疗前后的FDG PET-CT、PET-CT对比 ▲图源“N Engl J Med”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 小编寄语 CAR工程的出现引领了细胞治疗领域的变革，经CAR修饰后的NK细胞，能更加精准的对抗肿瘤细胞，CAR-NK细胞在临床研究中具有广阔的应用前景，在治疗血液肿瘤及部分实体瘤中，展现了令人惊艳的初步疗效及安全性。 如果您对目前的治疗方案存疑，或想寻求CAR-NK细胞、NK细胞、CAR-T细胞获国内外其他抗癌新技术的帮助，可扫文末二维码，将治疗经历、近期病理报告等，提交至国际干细胞与免疫细胞研究医学部，进行初步评估或申请国内外抗癌专家会诊。 参考资料 [1]Zhang X,et al.Cytokine release syndrome after modified CAR-NK therapy in an advanced non-small cell lung cancer patient: a case report[J]. Cell Transplantation, 2022, 31: 09636897221094244. https://journals.sagepub.com/doi/full/10.1177/09636897221094244 [2]Liu E,et al.Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020 Feb 6;382(6):545-553. [3]https://www.ajmc.com/view/long-term-cr-seen-with-allo-car-nk-cell-therapy-plus-rituximab-in-waldenstrom-nhl [4]https://immunitybio.com/immunitybio-reports-median-overall-survival-not-yet-reached-and-lymphopenia-reversed-in-recurrent-glioblastoma-patients-receiving-anktiva-plus-car-nk-chemo-free-therapy/ 本文为“国际干细胞与免疫细胞研究”原创，转载需授权 干细胞与免疫细胞研究 入群免费领取抗癌 细胞资讯｜新技术｜新药研发｜权威专家 资料 求分享 求收藏 求点击 求在看